التفاصيل البيبلوغرافية
| العنوان: |
Indirect comparisons of brigatinib and alectinib for front-line -positive non-small-cell lung cancer. |
| المؤلفون: |
Reckamp, Karen L, Lin, Huamao M, Cranmer, Holly, Wu, Yanyu, Zhang, Pingkuan, Walton, Laura J, Kay, Stephen, Cichewicz, Allie, Neupane, Binod, Fahrbach, Kyle, Popat, Sanjay, Camidge, D Ross |
| المصدر: |
Future Oncology; Jul2022, Vol. 18 Issue 20, p2499-2510, 12p |
| مصطلحات موضوعية: |
LUNG cancer, DISEASE progression, PROTEIN kinase inhibitors, HETEROCYCLIC compounds, ORGANOPHOSPHORUS compounds, LUNG tumors, PIPERIDINE, RESEARCH funding |
| مستخلص: |
Aim: To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive ALK-positive non-small-cell lung cancer (NSCLC). Methods: Final aggregate and patient-level data from the ALTA-1L trial comparing brigatinib to crizotinib and published aggregate data from ALEX (comparing alectinib to crizotinib) were contrasted using Bucher ITC and matching-adjusted indirect comparisons (MAICs). Results: No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall and in patients with baseline central nervous system metastases. Conclusion: Brigatinib appeared similar to alectinib in reducing risk of disease progression for people with TKI-naive ALK-positive NSCLC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
